ANDREW REGINALD CLARK
Pilots at Skyline Blvd, Redwood City, CA
License number
California A4221198
Issued Date
May 2016
Expiration Date
May 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
12290 Skyline Blvd, Redwood City, CA 94062
Professional information
Increased Dosage Metered Dose Inhaler
US Patent:
8079361, Dec 20, 2011
Filed:
Dec 17, 2008
Appl. No.:
12/337584
Inventors:
Carlos Schuler - Cupertino CA, US
Andrew R. Clark - Woodside CA, US
Kevin R. Walsh - San Francisco CA, US
William Alston - San Jose CA, US
Andrew R. Clark - Woodside CA, US
Kevin R. Walsh - San Francisco CA, US
William Alston - San Jose CA, US
Assignee:
Novartis AG - Basel
International Classification:
A61M 11/00
US Classification:
12820023, 12820014
Abstract:
An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.
Phospholipid-Based Powders For Inhalation
US Patent:
2004010, Jun 3, 2004
Filed:
Jul 8, 2003
Appl. No.:
10/616448
Inventors:
Jeffry Weers - Half Moon Bay CA, US
Thomas Tarara - Burlingame CA, US
Andrew Clark - Woodside CA, US
Thomas Tarara - Burlingame CA, US
Andrew Clark - Woodside CA, US
International Classification:
A61L009/04, A61K009/14
US Classification:
424/046000
Abstract:
Methods for inhalation are provided. The formulations for inhalation are engineered to be highly dispersible and provide rapid absorption of the active agent so delivered, as well as substantially independent emitted doses and lung deposition as functions of device resistance and inspiratory flow rates, respectively. The present invention also provides reductions in the flow rate dependence in lung deposition and improvements in patient reproducibility.
Formulation For Pulmonary Administration Of Antifungal Agents, And Associated Methods Of Manufacture And Use
US Patent:
8404217, Mar 26, 2013
Filed:
Jul 22, 2005
Appl. No.:
11/187757
Inventors:
Thomas E. Tarara - Burlingame CA, US
Jeffry G. Weers - Belmont CA, US
Michael A. Eldon - Redwood City CA, US
Rangachari Narashimhan - Thornhill, CA
Andrew Clark - Woodside CA, US
Jeffry G. Weers - Belmont CA, US
Michael A. Eldon - Redwood City CA, US
Rangachari Narashimhan - Thornhill, CA
Andrew Clark - Woodside CA, US
Assignee:
Novartis AG - Basel
International Classification:
A61L 9/04
US Classification:
424 45
Abstract:
Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.
Capsule Package With Moisture Barrier
US Patent:
2003010, Jun 12, 2003
Filed:
Dec 6, 2002
Appl. No.:
10/313419
Inventors:
Scot Cheu - San Jose CA, US
William Leung - Redwood City CA, US
Mei-Chang Kuo - Palo Alto CA, US
Andrew Clark - Woodside CA, US
William Leung - Redwood City CA, US
Mei-Chang Kuo - Palo Alto CA, US
Andrew Clark - Woodside CA, US
International Classification:
B65D083/04
US Classification:
206/531000, 206/528000
Abstract:
A package for storing an aerosolizable pharmaceutical formulation comprises a capsule adapted to contain the aerosolizable pharmaceutical formulation, and a moisture barrier around the capsule. The moisture barrier comprises a material that is resistant to moisture passage, whereby the moisture barrier reduces the amount of moisture in contact with the aerosolizable pharmaceutical formulation so that the aerosolizable pharmaceutical formulation may be aerosolized when the capsule is opened. In one version, the moisture barrier comprises a metal.
Methods For Tobramycin Inhalation
US Patent:
2002018, Dec 12, 2002
Filed:
May 7, 2002
Appl. No.:
10/141032
Inventors:
Jeffry Weers - Half Moon Bay CA, US
Thomas Tarara - Burlingame CA, US
Andrew Clark - Woodside CA, US
Thomas Tarara - Burlingame CA, US
Andrew Clark - Woodside CA, US
International Classification:
A61L009/04, A61K009/14
US Classification:
424/046000
Abstract:
Methods for inhalation are provided. The formulations for inhalation are engineered to be highly dispersible and provide rapid absorption of the active agent so delivered, as well as substantially independent emitted doses and lung deposition as functions of device resistance and inspiratory flow rates, respectively. The present invention also provides reductions in the flow rate dependence in lung deposition and improvements in patient reproducibility.
Increased Dosage Metered Dose Inhaler
US Patent:
7481212, Jan 27, 2009
Filed:
Oct 30, 2003
Appl. No.:
10/698025
Inventors:
Carlos Schuler - Cupertino CA, US
Andrew R. Clark - Woodside CA, US
Kevin R. Walsh - San Francisco CA, US
William Alston - San Jose CA, US
Andrew R. Clark - Woodside CA, US
Kevin R. Walsh - San Francisco CA, US
William Alston - San Jose CA, US
Assignee:
Nektar Therapeutics - San Carlos CA
International Classification:
A61M 11/00
US Classification:
12820023, 12820014
Abstract:
An aerosolization apparatus comprises a container containing a pharmaceutical formulation, the pharmaceutical formulation comprising an active agent and a propellant. The aerosolization apparatus further comprises a metering chamber in communication with the container, the metering chamber adapted to hold a metered amount of the pharmaceutical formulation, a valve to allow the metered amount of the pharmaceutical formulation to be released from the metering chamber when the valve is actuated, and a pressurizer that applies pressure to the pharmaceutical formulation in the metering chamber while the pharmaceutical formulation is being released from the metering chamber. In one version, the metering chamber is sized so that at least 2 mg, and preferably at least 5 mg, of the active agent is be aerosolized for delivery to a user during inhalation.